Nanolek is a Russian fast-growing pharmaceutical company which aims to become one of the market leaders in the production of innovative biotechnological products and modern vaccines, stimulating the creation of the national bioeconomy and amplifying the country’s biosafety. Nanolek’s product portfolio is formed in compliance with the priority therapeutic areas: cardiological and oncological products, innovative vaccines, including the cell-based influenza vaccine and the first Russian inactivated polio vaccine. In the meantime the company is also developing a number of biotech products, including new to the Russian market modern vaccines.